妫f牠銆�
閺堢喎鍨�: 瀵邦喕淇婇弬鍥╃彿 閸︺劎鍤庢稊锔剧潉 鐠у嫭鏋℃稉瀣祰 閸嬨儱鎮嶉弶鍌氱箶 閹躲儱鍨旈柅澶岀椽 閸╄櫣顢呴崠璇差劅 娑撴潙绨ラ崠璇差劅 閼筋垰顒� 鐎涳附濮� 娑擃厼娴楅崠璇差劅 閸楊偆鏁撻幀鏄忣啈
娣囨繂浠�: 閺備即妞� 鐠囧嫯顔� 鐟欏棛鍋� 鐢瓕鐦� 閻ゅ墽姊� 閻ュ洨濮� 閸忚崵鏁� 閻€劏宓� 閹躲倗鎮� 閹儲鏅� 閸嬨儴闊� 缂囧骸顔� 娑撱倖鈧拷 閼叉彃鍔� 閻拷 婵傦拷 閼帮拷 鐏忥拷 閸ユ稑顒� 鐠囪崵澧� 閺囨潙顦�
娑擃厼灏�: 鐢瓕鐦� 閺佹瑦娼� 閹繆鈧拷 娑擃叀宓� 閸栬崵鎮� 娑撴潙绨� 闁藉牓顎� 濮樻垶妫� 閺傚洤瀵� 閽佹ぞ缍� 妤犲本鏌� 閸ユ崘姘� 妞嬬喓鏋� 閼筋垳澧� 閼筋垯绗� 閼筋垰绔� 閺傛媽宓� 閹兼粎鍌� 閼昏鲸鏋�
当前位置: 首页 > 医学版 > 期刊论文 > 基础医学 > 病菌学杂志 > 2005年 > 第17期 > 正文
编号:11203079
Hepatitis A Virus Suppresses RIG-I-Mediated IRF-3

     Department of Virology, University of Bremen, D-28359 Bremen, Germany

    ABSTRACT

    Hepatitis A virus (HAV) antagonizes the innate immune response by inhibition of double-stranded RNA (dsRNA)-induced beta interferon (IFN-) gene expression. In this report, we show that this is due to an interaction of HAV with the intracellular dsRNA-induced retinoic acid-inducible gene I (RIG-I)-mediated signaling pathway upstream of the kinases responsible for interferon regulatory factor 3 (IRF-3) phosphorylation (TBK1 and IKK). In consequence, IRF-3 is not activated for nuclear translocation and gene induction. In addition, we found that HAV reduces TRIF (TIR domain-containing adaptor inducing IFN-)-mediated IRF-3 activation, which is part of the Toll-like receptor 3 signaling pathway. As IRF-3 is necessary for IFN- transcription, inhibition of this factor results in efficient suppression of IFN- synthesis. This ability of HAV seems to be of considerable importance for HAV replication, as HAV is not resistant to IFN-, and it may allow the virus to establish infection and preserve the sites of virus production in later stages of the infection.

    INTRODUCTION

    Hepatitis A virus (HAV), a member of the positive-stranded RNA picornavirus family, is transmitted by the fecal-oral route, but detours from the intestinal tract through the liver, which represents the site of viral replication (14, 23). At the cellular level, HAV infections result in a persistent noncytopathic infection (13, 21, 51). However, HAV is eliminated from the organism at later stages of the infection, and HAV infections do not result in viral persistence in the liver in vivo. This eradication of HAV from the organism, which is accompanied by massive hepatocyte destruction, is mediated mainly by the action of HAV-specific cytotoxic T lymphocytes (CTL) (18, 50). In addition, data were presented demonstrating that gamma interferon (IFN-) is produced after HAV stimulation by HAV-specific HLA-dependent CTL in vitro and may contribute to the elimination of HAV infections in humans by inducing an antiviral state in the later course of the infection (31). Furthermore, the experimental elimination of persistent HAV infections in human fibroblast cultures by exogenously added IFN-/ showed that HAV is not resistant to these interferons (49, 51). But neither measurable IFN-/ levels, which are normally produced rapidly in direct response to viral replication by virus-infected cells, nor interference with the infection by other viruses could be detected in lymphocytes and fibroblasts infected with HAV (51, 52), and the role of IFN-/ in the elimination of HAV during an acute infection was contradictorily discussed.

    Recently we confirmed that no IFN- is synthesized during an HAV infection in cell culture, as HAV prevents IFN- synthesis by interfering with double-stranded RNA (dsRNA) signaling (6). Using chloramphenicol acetyltransferase (CAT) as a reporter linked to the natural IFN- enhancer-promoter we could demonstrate that HAV does inhibit dsRNA-induced transcription of IFN-. We discussed that this ability of HAV, which, in concert with the ability to prevent apoptosis induced by accumulating dsRNA (6), preserves the sites of virus production for a longer time, allows spreading to neighboring cells, and helps the virus to establish an infection.

    The intention of our investigation was to find out at which site HAV interferes with the dsRNA-induced signaling cascade for induction of IFN- expression. The dsRNA-induced expression of IFN- is strictly regulated by the activation of preexisting transcription factors, such as interferon regulatory factor 3 (IRF-3), nuclear factor B (NF-B), and activating transcription factor 2/cellular Jun protein (ATF-2/c-Jun) (32). After activation by specific kinases, these factors translocate to the nucleus and interact with the coactivators p300/CBP (CREB binding protein) and bind to specific IFN- enhancer elements, termed positive regulatory domains III-I (IRF-3), II (NF-B), and IV (ATF-2/c-Jun), resulting in assembly of the transcription-inducing enhanceosome complex (47, 57; reviewed in references 1 and 32). In transfection experiments with reporter constructs containing the specific binding sites for the transcription factors, we found that HAV interferes with IRF-3 function. It has been shown that IRF-3 is activated by the TANK (TRAF family member-associated NF-B activator)-binding kinase 1 (TBK1) or the inhibitor of NF-B kinase (IKK) (16, 24, 34, 43). Recent work suggests that these kinases are activated through two independent signaling pathways, which are initiated by double-stranded RNA formed as a result of viral replication (see Fig. 8).

    Extracellular dsRNA binds to Toll-like receptor 3 (TLR3) (2, 33), which then recruits TBK1 via the adaptor protein TRIF (TIR domain-containing adaptor inducing IFN-) (37, 41, 56). For intracellular dsRNA, which accumulates during viral infections, two members of the caspase recruitment domain (CARD)-containing DExD/H box RNA helicases, retinoic acid-inducible gene I (RIG-I), and melanoma differentiation-associated gene 5 (MDA-5), have been identified as dsRNA receptors, which regulate downstream activation of the kinases TBK1/IKK (3, 8, 19, 58). Both pathways lead to IRF-3 phosphorylation, which results in formation of IRF-3 homodimers and in cytoplasmic to nuclear translocation (28, 30, 38, 45, 58, 59).

    We investigated the influence of HAV infection on the IRF-3 activation pathway and found that HAV interferes with TRIF signaling and blocks RIG-I signaling upstream of the IKK/TBK1 kinases, resulting in inhibition of IFN- transcription.

    MATERIALS AND METHODS

    Cells and transfections. Fetal rhesus monkey kidney cells (FRhK-4) and human embryonic lung fibroblasts (MRC-5) were maintained as continuous cultures in Dulbecco's modified Eagle's medium (DMEM) supplemented with 1% (FRhK-4) or 3% (MRC-5) fetal calf serum. In order to split the cells at a ratio of 1:2 (MRC-5) and 1:5 (FRhK-4), they were detached from the tissue culture plate with trypsin supplemented with 0.2 g of sodium-EDTA/liter and cultivated with Dulbecco's modified Eagle's medium-10% fetal calf serum as the growth medium.

    To establish stable cell lines containing the respective plasmids, the cells were transfected by calcium phosphate or jetPEI (Qbiogene) and cultured with selection medium containing 600 μg of G418 per ml.

    Transient transfections were performed in 58-mm dishes by jetPEI transfection of 5 μg plasmid as instructed by the manufacturer (Qbiogene).

    Polyinosinic-polycytidylic acid [poly(I-C)] transfection was performed with serum-free Dulbecco's modified Eagle's medium supplemented with 20 μg of poly(I-C)/ml in the presence of 100 μg of DEAE-dextran/ml for 2 h at 37°C. After one wash with phosphate-buffered saline, the cells were incubated for the times indicated.

    Viruses. HAV/7 (10), which is a variant of strain HM175, was propagated in FRhK-4 cells as described previously (7). HAV strain GBM (17) was propagated in MRC-5 cells. HAV-GBM, which is adapted to growth in MRC-5 cells, was used to investigate nuclear translocation of NF-B in MRC-5 cells. In all other experiments we used HAV/7. Newcastle disease virus (NDV) strain R 05/93, obtained from the Federal Research Center for Animal Health, Insel Riems, Germany, was passaged on FRhK-4 cells.

    The 50% tissue culture infective doses (TCID50) of HAV were determined by indirect immunofluorescence with the monoclonal mouse anti-HAV immunoglobulin G (IgG) antibody 7E7 (Mediagnost, Reutlingen, Germany), and the titer of NDV was determined by cytopathic effect. The titers were calculated by the Krber method (26).

    For experiments, HAV infections were carried out 10 days prior to analysis with a multiplicity of infection (MOI) of 1. In order to guarantee that all cells were infected, the cells were split 1 day prior to the experiments and infection of 100% of the cells was proved by indirect immunofluorescence.

    NDV replication kinetics under one-step growth conditions in FRhK-4 cells infected with HAV/7. FRhK-4 cells were infected with HAV/7 at an MOI of 1; 10 days after infection, when 100% of the cells were infected, as proved by immunofluorescence, cells were superinfected with NDV at an MOI of 10 and 0, 4, 8 and 24 h after NDV infection the 50% tissue culture infective dose titer was determined in FRhK-4 cells 6 days after inoculation by cytopathic effect. The titers were calculated by the Krber method (26). As controls for NDV replication, FRhK-4 cells not infected with HAV were used. This time frame corresponds to that used during the other experiments.

    CAT reporter assay. Cell extracts were prepared by triple freeze-thaw cycles, and expression of the CAT reporter gene was analyzed by subjecting 100 μg of protein to CAT-specific enzyme-linked immunosorbent assay (ELISA) (Roche) as described by the manufacturer. The detection limit of the assay was 10 pg/ml.

    Luciferase reporter assay. Cell extracts were prepared by triple freeze-thaw cycles, and luciferase reporter gene expression was analyzed by subjecting 20 μg of protein to the luciferase assay system (Promega) as described by the manufacturer by use of a luminometer (Wallac Microbeta).

    Immunoblot analysis. For analysis of IRF-3 phosphorylation, protein extracts were prepared with lysis buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM Na3VO4, 1% NP-40) supplemented with complete protease inhibitor cocktail (Roche). Under these conditions the phosphorylation status of proteins is maintained. Immunoblot analysis was conducted with 20 μg of protein as described earlier (12). The antibodies used were rabbit anti-IRF-3 (no. sc-9082, Santa Cruz) and bovine anti-rabbit-horseradish peroxidase (Santa Cruz). This procedure is a standard procedure described in the literature (30, 59) allowing the simultaneous detection of the two not-activated IRF-3 forms (IRF-3) and the activated, C-terminally phosphorylated IRF-3 (IRF-3-P). For Flag-RIG-I detection, mouse anti-Flag M2 (Sigma) and goat anti-mouse-horseradish peroxidase (Santa Cruz) were used. Visualization was performed with the ECL Western blotting analysis system from Amersham and Kodak Biomax films.

    Immunofluorescence analysis. Cells were cultured on Labtek chamber slides, then fixed and probed for HAV with mouse anti-HAV 7E7 (Mediagnost, Reutlingen, Germany), goat anti-mouse-fluorescein isothiocyanate or -Texas Red (KPL), for NF-B with rabbit anti-NF-B p65 (Santa Cruz), goat anti-rabbit-Biotin (Santa Cruz), and ExtrAvidin-fluorescein isothiocyanate (Sigma).

    Plasmids. The (–110-IFN-)-CAT, (PRDIII-I)3-CAT, (PRDII)2-CAT and (PRDIV)6-CAT plasmids were kindly provided by T. Maniatis, Harvard University, Cambridge, MA (47); pcDNA3/GFP-IRF-3(wt) by N. C. Reich, SUNY at Stony Brook, Stony Brook, NY (28); pCMVL/IRF-3(wt) by R. Lin, Lady Davis Institute, Montreal, Canada (30); (PRDIII-I)4-Luc by S. Ludwig, Heinrich Heine University, Düsseldorf, Germany (15); pcDNA3.1/IKK-myc by U. Siebenlist, National Institutes of Health, Bethesda, MD (9); pcDNA3/Flag-TBK1 (pcDNA3/Flag-NAK) by M. Nakanishi, Nagoya City University Medical School, Nagoya, Japan (48); pEF-Flag-RIG-Ifull, pEF-Flag-RIG-IC and p125-Luc (IFN--Luc) by T. Fujita, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan (58); and PL 1004 TRIF (Flag-TRIF) by J. Tschopp, University of Lausanne, Epalinges, Switzerland (35). Empty vectors were obtained by removing the inserted sequences.

    RESULTS

    HAV differentially affects transcriptional activity of the individual IFN- enhancer domains and interacts with IRF-3 signaling to inhibit dsRNA-induced IFN- synthesis. In former investigations it has been demonstrated by using a CAT reporter gene linked to the intact IFN- enhancer-promoter that HAV completely inhibits activation of the IFN- enhancer in response to dsRNA and therefore inhibits induction of IFN- mRNA transcription (6). In order to identify the target of HAV-mediated inhibition of IFN- transcription in the IFN- enhancer and thus the transcription factor with whose activity HAV interferes, we tested the ability of HAV to inhibit dsRNA-activated transcription from the individual regulatory domains of the IFN- enhancer. For this purpose, fetal rhesus monkey kidney cells (FRhK-4) were stably transfected with a CAT reporter gene linked to repeated individual enhancer elements (PRDII)2 (NF-B binding sites), (PRDIII-I)3 (IRF-3 binding sites), and (PRDIV)6 (ATF-2/c-Jun binding sites).

    In order to examine the influence of HAV on reporter gene expression, cells infected with HAV were transfected with 20 μg of the synthetic dsRNA analogon poly(I-C)/ml by DEAE-dextran. Extracellular poly(I-C) treatment without DEAE-dextran did not result in detectable reporter gene expression (not shown). In these experiments, HAV infection resulted in enhanced NF-B (PRDII)-dependent CAT expression compared with poly(I-C) induction alone (Fig. 1A). Additionally, HAV infection alone also resulted in significant reporter gene expression. These findings indicate that HAV infection induces activation of the pleiotropic transcription factor NF-B and show that inhibition of IFN- expression by HAV is not due to an interruption of NF-B signaling.

    Confirmation was obtained by investigating the nuclear translocation of this factor in cells infected with HAV and after poly(I-C) transfection by indirect immunofluorescence using antibodies specific for NF-B/p65. In cells neither infected with HAV nor transfected with poly(I-C), NF-B is localized mainly in the cytoplasm, whereas after induction with poly(I-C) as well as after poly(I-C) induction of HAV infected cells, NF-B is translocalized into the nucleus, which indicates NF-B activation (Fig. 1C). In cells solely infected with HAV NF-B translocation was also observed. HAV infection was confirmed by immunofluorescence using antibodies specific for HAV. In contrast to the experiment investigating PRDII-dependent CAT expression, in which we used HAV/7 and FRhK-4 cells, here we used HAV-GBM and MRC-5 cells. We could thus confirm that the influence of HAV on NF-B activation is independent of the virus strain and cell line used. This corresponds to our previous findings (6) that the influence of HAV on the induction of IFN- does not depend on the virus strain and the cell line.

    Induction of ATF-2/c-Jun (PRDIV)-controlled CAT expression by poly(I-C) was not affected by HAV (data not shown).

    Induction of IRF-3 (PRDIII-I)-dependent reporter gene expression was not detectable after HAV infection (Fig. 1B). Furthermore, IRF-3 activity, which was strongly induced by poly(I-C) transfection, was completely inhibited by HAV. Thus, HAV does not induce IRF-3 transcriptional activity but even interferes with IRF-3 signaling, consequently resulting in suppression of IFN- synthesis.

    HAV interferes with nuclear translocation and phosphorylation of IRF-3. In order to clarify whether HAV inhibits binding of IRF-3 to the corresponding PRDIII-I or whether intervention by HAV occurs further upstream in the signaling cascade, preventing nuclear translocation, FRhK-4 cells were stably transfected with IRF-3 linked to the green fluorescent protein (GFP) (FRhK-4/GFP-IRF-3) by calcium phosphate transfection and the subcellular localization of the protein was analyzed by fluorescence microscopy (Fig. 2A to D). GFP-IRF-3 was detected in the cytoplasm of these cells as well as in cells infected with HAV at an MOI of 1 10 days prior to analysis (Fig. 2A and B). After transfection of the cells with poly(I-C) (not shown) as well as after infection with Newcastle disease virus (NDV), which is a strong inducer of IRF-3 activity, at an MOI of 10 4 h prior to analysis, GFP-IRF-3 was mainly detected in the nucleus (Fig. 2C). NDV induction obviously occurs by viral dsRNA and therefore induction by NDV and by poly(I-C) transfection is functionally equivalent, which will be demonstrated below. In cells infected with HAV, which does not interfere with NDV replication (Fig. 3), translocation of IRF-3 to the nucleus could never be detected after stimulation with NDV (Fig. 2D) or transfection with poly(I-C). HAV infection of 100% of the cells was visualized by immunofluorescence. These results imply that HAV already prevents activation of IRF-3 in the cytoplasm.

    To further clarify this, we stably transfected FRhK-4 cells with IRF-3 (FRhK-4/IRF-3) and analyzed the phosphorylation status of IRF-3 at different times after induction by NDV (MOI 10) in cells infected with HAV by immunoblot analysis. Cells overexpressing IRF-3 were used as due to low concentrations, phosphorylated endogenous IRF-3 could not be detected by immunoblot analysis; 4 h after infection with NDV, phosphorylation of IRF-3 was observed by the occurence of an additional, slower migrating form (Fig. 2E) compared to the two not-activated IRF-3 forms (30, 59). In cells infected with HAV, NDV-mediated phosphorylation of IRF-3 was completely inhibited. HAV infection was confirmed by immunofluorescence, and NDV infection by appearance of cytopathic effects. The results demonstrate that HAV prevents phosphorylation and thus activation and nuclear translocation of IRF-3.

    HAV does not directly interfere with the activity of IKK and TBK1. In order to further analyze the stage at which HAV interferes with phosphorylation of IRF-3, we first investigated whether HAV is able to inhibit the activity of the kinases responsible for IRF-3 phosphorylation (see Fig. 8). FRhK-4 cells infected with HAV were cotransfected with CAT or luciferase as a reporter gene linked to the intact IFN- enhancer-promoter (IFN--CAT and IFN--Luc) or to repeated PRDIII-I domains for specific detection of activated IRF-3 (PRDIII-I-CAT, and PRDIII-I-Luc) and a plasmid for constitutive expression of IKK or TBK1, respectively, 10 days postinfection. Noninfected cells were used as references.

    As demonstrated by different laboratories, overexpression of the kinases results in kinase activity without additional activation (8, 16, 43) and 42 h after transfection reporter gene expression was analyzed. In cells overexpressing IKK (Fig. 4A) or TBK1 (Fig. 4B), significant reporter gene expression was detected. This shows that each of the individual kinases activates IRF-3 and induces IFN- under these experimental conditions. In cells infected with HAV, reporter gene expression and therefore the activity of the kinases were not affected. In order to prove functional HAV infection of the cells, they were cotransfected with the reporter plasmid and the empty vectors for the kinases. As expected, NDV-induced reporter gene expression was completely inhibited in HAV-infected cells. In addition, with cells overexpressing TBK1 and infected with NDV it was shown by using PRDIII-I-controlled luciferase expression that HAV is able to inhibit NDV-induced IRF-3 activation independently of TBK1 activity resulting from kinase overexpression (Fig. 4B, right). In these experiments luciferase expression was reduced by HAV to levels observed with overexpressed TBK1 alone.

    These results demonstrate that HAV does not interfere either directly with IKK and TBK1, thus not inhibiting kinase activity, or directly with IRF-3, thus not inhibiting IRF-3 phosphorylation and activity, but imply that inhibition of IRF-3 phosphorylation is the result of an intervention of HAV with dsRNA signaling upstream of the kinases, preventing their activation.

    HAV inhibits RIG-I-mediated signaling. The results described above indicate that the target site of inhibition of dsRNA-induced IFN- synthesis by HAV is located upstream of the activator kinase complex for IRF-3. Therefore, we investigated the influence of HAV on signaling initiated by RIG-I, which acts as an intracellular dsRNA receptor regulating IRF-3 activation and thence IFN- induction. Constitutive RIG-I expression was detected at low basal levels in FRhK-4 cells by reverse transcription-PCR (not shown). FRhK-4 cells cotransfected with a RIG-I expression plasmid and a CAT reporter construct containing the complete IFN- enhancer or repeated IRF-3 binding sites (PRDIII-I) were analyzed for CAT expression 42 h after transfection. As shown in Fig. 5, overexpression of RIG-I, proved by immunoblot detection, resulted in significant CAT expression. In cells infected with HAV, which does not influence RIG-I expression (Fig. 5, lower panels), however, CAT expression controlled by the complete IFN- enhancer (Fig. 5A) as well as by PRDIII-I (Fig. 5B) was inhibited completely. As RIG-I overexpression did not complement the inhibitory effect of HAV, it can be assumed that HAV does interact with signaling downstream of RIG-I.

    Furthermore, we were able to show that NDV-mediated reporter gene induction, which we used in some parts of our experiments, is mediated by NDV dsRNA. FRhK-4 cells were cotransfected with an IFN--CAT reporter construct and with a RIG-IC expression plasmid, which encodes the dsRNA-binding helicase domain but not the signal-transducing CARD domain and exhibits a dominant negative effect by sequestering dsRNA molecules. As expected (58), RIG-IC overexpression prevented IFN--CAT expression induced by poly(I-C) transfection (Fig. 6A) or NDV infection (Fig. 6B), suggesting functional equivalence of the two inductors and even more demonstrating exclusively intracellular, TLR3-independent dsRNA signaling.

    These experiments demonstrate that HAV prevents IFN- synthesis by inhibiting activation of endogenous IRF-3 by blocking intracellular dsRNA-induced RIG-I-mediated downstream signaling.

    In order to investigate whether HAV also impairs the TLR3 pathway-associated TRIF-mediated induction of IFN- and IRF-3 activation, FRhK-4 cells were cotransfected with a TRIF expression plasmid and a CAT reporter construct containing the complete IFN- enhancer or repeated IRF-3 binding sites (PRDIII-I) (Fig. 7). Analysis of CAT expression was performed 42 h after transfection. As with RIG-I, overexpression of TRIF, which is constitutively expressed in FRhK-4 cells at basal levels (not shown), also resulted in significant CAT expression, but in cells infected with HAV CAT expression controlled by the complete IFN- enhancer (Fig. 7 A) as well as by PRDIII-I (Fig. 7 B) was not inhibited completely, but reduced up to 50%. In addition to the presence of HAV in 100% of the cells, as proved by immunofluorescence, functional HAV infection of the cells was confirmed by the demonstration that reporter gene expression induced by NDV (Fig. 7B) or by RIG-I (shown in Fig. 5A; data shown in Fig. 5A and 7A represent results of a combined experiment) was completely inhibited. This shows that HAV is able to reduce TRIF-mediated activation of IRF-3, but seems to be well adapted to interfere with the RIG-I signaling pathway, which means with intracellular dsRNA-induced IFN- synthesis.

    DISCUSSION

    Previously we proved that HAV infections in general do not result in IFN- expression and that this is due to the ability of HAV to inhibit dsRNA-mediated transcriptional induction of IFN- (6). In this study, we investigated with what section of the dsRNA-signaling cascade HAV interferes to prevent dsRNA-induced transcription of IFN-, thereby antagonizing the innate antiviral immune response.

    Using plasmid constructs with the individual domains of the IFN- enhancer linked to reporter genes, we showed that inhibition of IFN- transcription by HAV occurs through a mechanism influencing IRF-3 activity. Whereas transcription factor ATF-2/c-Jun activation is not affected by HAV and transcription factor NF-B activation is even enhanced, the activity of transcription factor IRF-3 is completely inhibited. We demonstrated that HAV prevents IRF-3 phosphorylation, which is necessary for IRF-3 dimerization and cytoplasm-to-nucleus translocation (Fig. 8). Obviously HAV does not interact either with IRF-3 or with the IKK/TBK1 kinases directly, because in the case of IKK and TBK1 overexpression, HAV does not alter IRF-3 activity. Based on our data, we conclude that HAV prevents IKK/TBK1 kinase activation by inhibiting dsRNA-controlled and RIG-I-mediated downstream signaling to the kinases, which represents a pathway essential for viral triggering of IRF-3 activation and IFN- induction in hepatocytes as well as in HeLa cells and L929 mouse fibroblasts (29, 46, 58).

    As RIG-I activity obtained by overexpression of the protein and not by dsRNA induction is completely inhibited by HAV, it appears that HAV does not mask dsRNA. This is further supported by two observations. First, large amounts of intracellular dsRNA obtained by poly(I-C) transfection or NDV infection do not compete with the inhibition by HAV. Second, activation of NF-B by dsRNA is not suppressed by HAV. Also, HAV does not seem to interact directly with RIG-I, as overexpression of RIG-I does not compete with the inhibitory effect caused by HAV. Based on our experimental findings we can conclude that HAV interacts with intracellular dsRNA-induced signal transduction downstream of RIG-I or a protein functionally similar to RIG-I, such as MDA-5 (3), and upstream of the IKK/TBK1 kinase complex, thus preventing IRF-3 phosphorylation and in consequence IFN- synthesis. At present, it is not possible to determine the site of HAV intervention more exactly, as the components of the pathway connecting RIG-I with the kinases have not been identified. Recently, Balachandran et al. (4) proposed an involvement of the adaptor Fas-associated death domain (FADD) and the RIP1 kinase in intracellular dsRNA signaling, providing possible targets for HAV.

    IRF-3 activation and IFN- induction are also possible through TLR3 signaling, a pathway normally initiated in response to extracellular dsRNA (16). However, in FRhK-4 cells extracellular dsRNA treatment did not result in IFN- induction, although TLR3 mRNA could be detected (not shown). As TLR3 is known to be mainly associated with intracellular vesicular structures (20, 36), activation by HAV replication, which also occurs in association with intracellular vesicles (44), seems possible. In this case, signaling would be transduced by the adaptor molecule TRIF, which forms a complex with TLR3, TBK1, and IRF-3, thus activating the kinase and thence IRF-3 (41). We demonstrated that HAV also has the ability to affect this transduction pathway. The only partial inhibition of the TRIF-mediated signal transduction by HAV which we observed in our experiments may result from competition with surplus TRIF, which was overexpressed and may therefore counteract suppression by HAV, implying a direct interaction with TRIF.

    The effectiveness of the interferon response has caused many viruses to develop specific mechanisms to antagonize the antiviral effects (for reviews, see references 22 and 42). Viruses vary considerably in their ability to prevent the production or actions of IFNs and several of them interact with IRF-3 function to inhibit IFN- synthesis. For example, influenza A virus NS1 protein and vaccinia virus E3L protein mask dsRNA, thus preventing induction of the signaling cascade (53, 55), whereas human papillomavirus E6 protein and rotavirus NSP1 protein bind directly to IRF-3 (5, 39). Sendai virus V protein interacts with MDA-5, thus inhibiting intracellular dsRNA signaling (3). Similar to HAV, hepatitis C virus antagonizes dsRNA-activated RIG-I and TLR3 signaling. Whereas proteolytic cleavage of a not yet identified RIG-I pathway component by NS3/4A protease of hepatitis C virus is assumed, it could be demonstrated that this protease causes specific proteolysis of TRIF (19, 29, 46). As IRF-3 activity is necessary for IFN- transcription (40, 59), this factor represents an excellent target for interventions to achieve suppression of IFN- synthesis.

    The competence of HAV to directly modulate the host cell's antiviral IFN response seems to be of considerable importance for HAV replication, as HAV is not resistant to IFN- (49, 51). After entry into host cells, HAV replicates exceptionally slowly. The ability to inhibit dsRNA-induced transcriptional activation of IFN- guarantees that no antiviral activities by IFN-stimulated genes are induced in the already infected cells as well as in surrounding noninfected cells. This strategy may allow HAV to establish and preserve infection and may be the basis for the persistent character of HAV infections.

    In addition, the inhibition of dsRNA-induced RIG-I signaling by HAV may allow the virus to evade the cellular IFN response for a longer time at later stages of the infection. At that time, RIG-I expression may be upregulated by IFN- (11, 25), which is secreted by HAV-specific CTL (31), enhancing the responsiveness of cells to viral dsRNA. As HAV obviously does not interact with RIG-I directly, HAV may be able to further inhibit signaling in this situation, because larger amounts of RIG-I are not able to competitively overcome inhibition at the site where HAV interferes.

    Furthermore, since IRF-3 is also involved in induction of apoptosis by dsRNA (54) and since HAV is also able to inhibit dsRNA-induced apoptosis (6), HAV may not only inhibit IFN- synthesis by suppression of IRF-3 activation; this mechanism may also support inhibition of apoptosis. We found that HAV enhances activation of transcription factor NF-B. As this pleiotropic factor is involved in expression of antiapoptotic genes (reviewed in reference 27), the ability of HAV to activate NF-B may play a role in inhibition of apoptosis by this virus.

    In summary, we localized the site at which HAV inhibits dsRNA-induced IFN expression, in the RIG-I-mediated signaling cascade upstream of the kinases for IRF-3 phosphorylation. It remains to be shown through which viral factors HAV is able to interfere with the RIG-I and TLR3 signaling pathways and whether suppression of IRF-3 activity by HAV may contribute to inhibition of apoptosis.

    ACKNOWLEDGMENTS

    We thank T. Fujita, R. Lin, S. Ludwig, T. Maniatis, M. Nakanishi, N. C. Reich, U. Siebenlist, and J. Tschopp for providing plasmids and Mediagnost, Reutlingen, Germany, for providing the monoclonal anti-HAV antibody 7E7.

    This work was supported by grant BFK no. 02/105/2 of the University of Bremen, Bremen, Germany, and by the Tnjes-Vagt-Stiftung, Bremen, Germany.

    REFERENCES

    Akira, S., and K. Takeda. 2004. Toll-like receptor signalling. Nat. Rev. Immunol. 4:499-511.

    Alexopoulou, L., A. C. Holt, R. Medzhitov, and R. A. Flavell. 2001. Recognition of double-stranded RNA and activation of NF-B by toll-like receptor 3. Nature 413:732-738.

    Andrejeva, J., K. S. Childs, D. F. Young, T. S. Carlos, N. Stock, S. Goodbourn, and R. E. Randall. 2004. The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN- promoter. Proc. Natl. Acad. Sci. USA 101:17264-17269.

    Balachandran, S., E. Thomas, and G. N. Barber. 2004. A FADD-dependent innate immune mechanism in mammalian cells. Nature 432:401-405.

    Barro, M., and J. T. Patton. 2005. Rotavirus nonstructural protein 1 subverts innate immune response by inducing degradation of IFN regulatory factor 3. Proc. Natl. Acad. Sci. USA 102:4114-4119.

    Brack, K., I. Berk, T. Magulski, J. Lederer, A. Dotzauer, and A. Vallbracht. 2002. Hepatitis A virus inhibits cellular antiviral defense mechanisms induced by double-stranded RNA. J. Virol. 76:11920-11930.

    Brack, K., W. Frings, A. Dotzauer, and A. Vallbracht. 1998. A cytopathogenic, apoptosis-inducing variant of hepatitis A virus. J. Virol. 72:3370-3376.

    Breiman, A., N. Grandvaux, R. Lin, C. Ottone, S. Akira, M. Yoneyama, T. Fujita, J. Hiscott, and E. F. Meurs. 2005. Inhibition of RIG-I-dependent signaling to the interferon pathway during hepatitis C virus expression and restoration of signaling by IKK. J. Virol. 79:3969-3978.

    Chariot, A., A. Leonardi, J. Müller, M. Bonif, K. Brown, and U. Siebenlist. 2002. Association of the adaptor TANK with the IB kinase (IKK) regulator NEMO connects IKK complexes with IKK and TBK1 kinases. J. Biol. Chem. 277:37029-37036.

    Cohen, J. I., B. Rosenblum, J. T. Ticehurst, R. J. Daemer, S. M. Feinstone, and R. H. Purcell. 1987. Complete nucleotide sequence of an attenuated hepatitis A virus: comparison with wild-type virus. Proc. Natl. Acad. Sci. USA 84:2497-2501.

    Cui, X.-F., T. Imaizumi, H. Yoshida, E. C. Borden, and K. Satoh. 2004. Retinoic acid-inducible gene-I is induced by interferon- and regulates the expression of interferon- stimulated gene 15 in MCF-7 cells. Biochem. Cell Biol. 82:401-405.

    Dotzauer, A., A. Vallbracht, and G. M. Keil. 1995. The proposed gene for VP1 of HAV encodes for a larger protein than that observed in HAV-infected cells and virions. Virology 213:671-675.

    Dotzauer, A., S. M. Feinstone, and G. Kaplan. 1994. Susceptibility of nonprimate cell lines to hepatitis A virus infection. J. Virol. 68:6064-6068.

    Dotzauer, A., U. Gebhardt, K. Bieback, U. Gttke, A. Kracke, J. Mages, S. M. Lemon, and A. Vallbracht. 2000. Hepatitis A virus-specific immunoglobulin A mediates infection of hepatocytes with hepatitis A virus via the asialoglycoprotein receptor. J. Virol. 74:10950-10957.

    Ehrhardt, C., C. Kardinal, W. J. Wurzer, T. Wolff, C. von Eichel-Streiber, S. Pleschka, O. Planz, and S. Ludwig. 2004. Rac1 and PAK1 are upstream of IKK- and TBK-1 in the viral activation of interferon regulatory factor-3. FEBS Lett. 567:230-238.

    Fitzgerald, K. A., S. M. McWhirter, K. L. Faia, D. C. Rowe, E. Latz, D. T. Golenbock, A. J. Coyle, S.-M. Liao, and T. Maniatis. 2003. IKK and TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol. 4:491-496.

    Flehmig, B., H. Frank, G. G. Frsner, and H.-J. Gerth. 1977. Hepatitis A-virus particles in stools of patients from a natural hepatitis outbreak in Germany. Med. Microbiol. Immunol. 163:209-214.

    Fleischer, B., S. Fleischer, K. Maier, K. H. Wiedmann, M. Sacher, H. Thaler, and A. Vallbracht. 1990. Clonal analysis of infiltrating T lymphocytes in liver tissue in viral hepatitis A. Immunology 69:14-19.

    Foy, E., K. Li, R. Sumpter, Jr., Y.-M. Loo, C. L. Johnson, C. Wang, P. M. Fish, M. Yoneyama, T. Fujita, S. M. Lemon, and M. Gale, Jr. 2005. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc. Natl. Acad. Sci. USA 102:2986-2991.

    Funami, K., M. Matsumoto, H. Oshiumi, T. Akazawa, A. Yamamoto, and T. Seya. 2004. The cytoplasmic ‘linker region’ in toll-like receptor 3 controls receptor localization and signaling. Int. Immunol. 16:1143-1154.

    Gauss-Müller, V., and F. Deinhardt. 1984. Effect of hepatitis A virus infection on cell metabolism in vitro. Proc. Soc. Exp. Biol. Med. 175:10-15.

    Goodbourn, S., L. Didcock, and R. E. Randall. 2000. Interferons: cell signalling, immune modulation, antiviral responses and virus countermeasures. J. Gen. Virol. 81:2341-2364.

    Gust, I. D., and S. M. Feinstone. 1988. Hepatitis A. CRC Press, Inc., Boca Raton, Fla.

    Hemmi, H., O. Takeuchi, S. Sato, M. Yamamoto, T. Kaisho, H. Sanjo, T. Kawai, K. Hoshino, K. Takeda, and S. Akira. 2004. The roles of two IB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection. J. Exp. Med. 199:1641-1650.

    Imaizumi, T., N. Yagihashi, M. Hatakeyama, K. Yamashita, A. Ishikawa, K. Taima, H. Yoshida, S. Yagihashi, and K. Satoh. 2004. Upregulation of retinoic acid-inducible gene-I in T24 urinary bladder carcinoma cells stimulated with interferon-. Tohoku J. Exp. Med. 203:313-318.

    Krber, G. 1931. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch. Exp. Pathol. Pharmakol. 162:480-483.

    Kucharczak, J., M. J. Simmons, Y. Fan, and C. Gélinas. 2003. To be, or not to be: NF-B is the answer-role of Rel/NF-B in the regulation of apoptosis. Oncogene 22:8961-8982.

    Kumar, K. P., K. M. McBride, B. K. Weaver, C. Dingwall, and N. C. Reich. 2000. Regulated nuclear-cytoplasmic localization of interferon regulatory factor 3, a subunit of double-stranded RNA-activated factor 1. Mol. Cell. Biol. 20:4159-4168.

    Li, K., E. Foy, J. C. Ferreon, M. Nakamura, A. C. M. Ferreon, M. Ikeda, S. C. Ray, M. Gale, Jr., and S. M. Lemon. 2005. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the toll-like receptor 3 adaptor protein TRIF. Proc. Natl. Acad. Sci. USA 102:2992-2997.

    Lin, R., C. Heylbroeck, P. M. Pitha, and J. Hiscott. 1998. Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome-mediated degradation. Mol. Cell. Biol. 18:2986-2996.

    Maier, K., P. Gabriel, E. Koscielniak, Y.-D. Stierhof, K. H. Wiedmann, B. Flehmig, and A. Vallbracht. 1988. Hum. gamma interferon production by cytotoxic T lymphocytes sensitized during hepatitis A virus infection. J. Virol. 62:3756-3763.

    Maniatis, T., J. V. Falvo, T. H. Kim, T. K. Kim, C. H. Lin, B. S. Parekh, and M. G. Wathelet. 1998. Structure and function of the interferon- enhanceosome. Cold Spring Harb. Symp. Quant. Biol. 63:609-620.

    Matsumoto, M., S. Kikkawa, M. Kohase, K. Miyake, and T. Seya. 2002. Establishment of a monoclonal antibody against human toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. Biochem. Biophys. Res. Commun. 293:1364-1369.

    McWhirter, S. M., K. A. Fitzgerald, J. Rosains, D. C. Rowe, D. T. Golenbock, and T. Maniatis. 2004. IFN-regulatory factor 3-dependent gene expression is defective in Tbk1-deficient mouse embryonic fibroblasts. Proc. Natl. Acad. Sci. USA 101:233-238.

    Meylan, E., K. Burns, K. Hofmann, V. Blancheteau, F. Martinon, M. Kelliher, and J. Tschopp. 2004. RIP1 is an essential mediator of toll-like receptor 3-induced NF-B activation. Nat. Immunol. 5:503-507.

    Nishiya, T., and A. L. DeFranco. 2004. Ligand-regulated chimeric receptor approach reveals distinctive subcellular localization and signaling properties of the toll-like receptors. J. Biol. Chem. 279:19008-19017.

    Oshiumi, H., M. Matsumoto, K. Funami, T. Akazawa, and T. Seya. 2003. TICAM-1, an adaptor molecule that participates in toll-like receptor 3-mediated interferon- induction. Nat. Immunol. 4:161-167.

    Perry, A. K., E. K. Chow, J. B. Goodnough, W.-C. Yeh, and G. Cheng. 2004. Differential requirement for TANK-binding kinase-1 in type I interferon responses to toll-like receptor activation and viral infection. J. Exp. Med. 199:1651-1658.

    Ronco, L. V., A. Y. Karpova, M. Vidal, and P. M. Howley. 1998. Hum. papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev. 12:2061-2072.

    Sato, M., H. Suemori, N. Hata, M. Asagiri, K. Ogasawara, K. Nakao, T. Nakaya, M. Katsuki, S. Noguchi, N. Tanaka, and T. Taniguchi. 2000. Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-/ gene induction. Immunity 13:539-548.

    Sato, S., M. Sugiyama, M. Yamamoto, Y. Watanabe, T. Kawai, K. Takeda, and S. Akira. 2003. Toll/IL-1 receptor domain-containing adaptor inducing IFN- (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF-B and IFN-regulatory factor-3, in the toll-like receptor signaling. J. Immunol. 171:4304-4310.

    Sen, G. C. 2001. Viruses and interferons. Annu. Rev. Microbiol. 55:255-281.

    Sharma, S., B. R. tenOever, N. Grandvaux, G.-P. Zhou, R. Lin, and J. Hiscott. 2003. Triggering the interferon antiviral response through an IKK-related pathway. Science 300:1148-1151.

    Stierhof, Y.-D. 1989. Ph.D. thesis. Eberhard-Karls-Universitt, Tübingen, Germany.

    Suhara, W., M. Yoneyama, T. Iwamura, S. Yoshimura, K. Tamura, H. Namiki, S. Aimoto, and T. Fujita. 2000. Analyses of virus-induced homomeric and heteromeric protein associations between IRF-3 and coactivator CBP/p300. J. Biochem. 128:301-307.

    Sumpter, Jr., R., Y.-M. Loo, E. Foy, K. Li, M. Yoneyama, T. Fujita, S. M. Lemon, and M. Gale, Jr. 2005. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J. Virol. 79:2689-2699.

    Thanos, D., and T. Maniatis. 1995. Virus induction of human IFN gene expression requires the assembly of an enhanceosome. Cell 83:1091-1100.

    Tojima, Y., A. Fujimoto, M. Delhase, Y. Chen, S. Hatakeyama, K.-I. Nakayama, Y. Kaneko, Y. Nimura, N. Motoyama, K. Ikeda, M. Karin, and M. Nakanishi. 2000. NAK is an IB kinase-activating kinase. Nature 404:778-782.

    Vallbracht, A., and B. Flehmig. 1985. Elimination of a persistent hepatitis A infection in cell cultures by interferon, p. 339-345. In H. Kirchner and H. Schellekens (ed.), The biology of the interferon system 1984. Elsevier Science Publishers B.V., Amsterdam, The Netherlands.

    Vallbracht, A., K. Maier, Y.-D. Stierhof, K. H. Wiedmann, B. Flehmig, and B. Fleischer. 1989. Liver-derived cytotoxic T cells in hepatitis A virus infection. J. Infect. Dis. 160:209-217.

    Vallbracht, A., L. Hofman, K. G. Wurster, and B. Flehmig. 1984. Persistent infection of human fibroblasts by hepatitis A virus. J. Gen. Virol. 65:609-615.

    Vallbracht, A., P. Gabriel, J. Zahn, and B. Flehmig. 1985. Hepatitis A virus infection and the interferon system. J. Infect. Dis. 152:211-213.

    Wang, X., M. Li, H. Zheng, T. Muster, P. Palese, A. A. Beg, and A. García-Sastre. 2000. Influenza A virus NS1 protein prevents activation of NF-B and induction of alpha/beta interferon. J. Virol. 74:11566-11573.

    Weaver, B. K., O. Ando, K. P. Kumar, and N. C. Reich. 2001. Apoptosis is promoted by the dsRNA-activated factor (DRAF1) during viral infection independent of the action of interferon or p53. FASEB J. 15:501-514.

    Xiang, Y., R. C. Condit, S. Vijaysri, B. Jacobs, B. R. G. Williams, and R. H. Silverman. 2002. Blockade of interferon induction and action by the E3L double-stranded RNA binding proteins of vaccinia virus. J. Virol. 76:5251-5259.

    Yamamoto, M., S. Sato, K. Mori, K. Hoshino, O. Takeuchi, K. Takeda, and S. Akira. 2002. A novel toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN- promoter in the toll-like receptor signaling. J. Immunol. 169:6668-6672.

    Yang, H., G. Ma, C. H. Lin, M. Orr, M. G. Wathelet. 2004. Mechanism for transcriptional synergy between interferon regulatory factor (IRF)-3 and IRF-7 in activation of the interferon- gene promoter. Eur. J. Biochem. 271:3693-3703.

    Yoneyama, M., M. Kikuchi, T. Natsukawa, N. Shinobu, T. Imaizumi, M. Miyagishi, K. Taira, S. Akira, and T. Fujita. 2004. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 5:730-737.

    Yoneyama, M., W. Suhara, Y. Fukuhara, M. Fukuda, E. Nishida, and T. Fujita. 1998. Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300. EMBO J. 17:1087-1095.(Volker Fensterl, Dajana G)
    婵烇絽娲犻崜婵囧閸涱喚顩烽柛娑卞墰鏉╂棃鏌涘▎蹇撯偓浠嬪焵椤掆偓閸犳稓妲愬┑鍥┾枖鐎广儱妫涢埀顒夊灦楠炲骞囬鍛簥婵炶揪绲惧ú鎴犵不閿濆拋鍤堝Δ锔筋儥閸炴挳鏌曢崱鏇犲妽閻㈩垰缍婇幊锟犲箛椤撶偟浠愰梺鍦瑰ú銈囨閳哄懎违闁稿本绋掗悗顔剧磼閺冨倸啸濠⒀勵殜瀵爼宕橀妸褎鍓戞繛瀛樼矊妤犲摜鏁锔藉婵$偛澧界粙濠囨煛婢跺﹤鏆曟慨鐟邦樀閺佸秴鐣濋崘顭戜户闂佽鍠撻崝蹇涱敇缂佹ḿ鈻旈柣鎴烇供閸斿啴鏌¢崒姘煑缂佹顦遍埀顒冾潐缁繘锝為敃鍌氱哗閻犻缚娅g粔鍨€掑顓犫槈闁靛洤娲ㄩ埀顒傤攰濞夋盯宕㈤妶鍥ㄥ鐟滅増甯楅~澶愭偣閸ワ妇涓茬紒杈ㄧ箘閹风娀鎮滈挊澶夌病婵炲濮鹃崺鏍垂閵娾晜鍋ㄥù锝呭暟濡牓姊洪锝嗙殤闁绘搫绻濋獮瀣箣濠婂嫮鎷ㄩ梺鎸庣☉閺堫剟宕瑰⿰鍕浄妞ゆ帊鐒﹂弳顏堟煕閹哄秴宓嗛柍褜鍓氬銊╂偂閿熺姴瑙﹂幖鎼灣缁€澶娒归崗鍏肩殤闁绘繃鐩畷锟犲礃閼碱剚顔戦梺璇″枔閸斿骸鈻撻幋鐐村婵犲﹤鍟幆鍌毭归悩鎻掝劉婵犫偓閹殿喚纾鹃柟瀵稿Х瑜版煡鏌涢幒鏂库枅婵炲懎閰f俊鎾晸閿燂拷

   閻庣敻鍋婇崰鏇熺┍婵犲洤妫橀柛銉㈡櫇瑜帮拷  闂佺ǹ绻楀▍鏇㈠极閻愮儤鍎岄柣鎰靛墮椤庯拷  闁荤姴娲ょ€氼垶顢欓幋锕€绀勯柣妯诲絻缂嶏拷  闂佺懓鍚嬬划搴ㄥ磼閵娾晛鍗抽柡澶嬪焾濡拷   闂佽浜介崝宀勬偤閵娧呯<婵炲棙鍔栫粻娆撴煕濞嗘瑦瀚�   闂佸憡姊绘慨鎾矗閸℃稑缁╅柟顖滃椤ワ拷